Arman Ahmadzadeh

Arman Ahmadzadeh

Auto-generated profile, based on publicly available information

Arman Ahmadzadeh

Department of Adult Rheumatology, Loghman Hakim Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Dermatology Research and Practice
Verified
Journal Article
Open access
PDF file
MGMehdi Gheisari
Mehdi Gheisari
AAArman Ahmadzadeh
Arman Ahmadzadeh
NNNilofar Nobari
Nilofar Nobari
BIBehzad Iranmanesh
Behzad Iranmanesh
NMNikoo Mozafari
Nikoo Mozafari
Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of autologous fat grafting in the face of patients with systemic sclerosis. We enrolled 16 SSc patients suffering from facial sclerosis and limited mouth opening capacity. Autologous fat injection ranging from 15 to 40 ml was administered per patient, based on their face morphology. The patients were evaluated at baseline and 3 months after fat injection. Evaluations included mouth opening capacity, mouth handicap in systemic sclerosis (MHISS), Rodnan skin sclerosis score, skin biophysical properties using a sensitive biometrologic device with the assessment of cutaneous resonance running time (CRRT), volumizing and aesthetic effects based on pre- and posttreatment photographs, possible side effects, and global patient satisfaction. Clinical assessment showed autologous fat transfer significantly improved mouth opening capacity and the MHISS and Rodnan score of patients with facial scleroderma (p value <.001). The aesthetic and/or functional results of fat injection were satisfying to about 80% of the patients. The changes in CRRT values were not significant. Our findings support the possible therapeutic role of autologous fat grafting in improving facial scleroderma both in aesthetic and in functional aspects. This trial is registered with IRCT20180209038677N1.

20 July 2017 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
AJAhmadreza Jamshidi
Ahmadreza Jamshidi
FGFarhad Gharibdoost
Farhad Gharibdoost
MVMahdi Vojdanian
Mahdi Vojdanian
SSSoosan Soroosh
Soosan Soroosh
MSMohsen Soroush
Mohsen Soroush
ARAmin Mohammadinejad Rashti
Amin Mohammadinejad Rashti
This study aimed to compare efficacy and safety of test-adalimumab (CinnoRA®, CinnaGen, Iran) to the innovator product (Humira®, AbbVie, USA) in adult patients with active rheumatoid arthritis (RA). In this randomized, double-blind, active-controlled, non-inferiority trial, a total of 136 patients with active RA were randomized to receive 40 mg subcutaneous injections of either CinnoRA® or Humira® every other week, while receiving methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over a period of 24 weeks. Physical examinations, vital sign evaluations, and laboratory tests were conducted in patients at baseline and at 12-week and 24-week visits. The primary endpoint in this study was the proportion of patients achieving moderate and good disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR)-based European League Against Rheumatism (EULAR) response. The secondary endpoints were the proportion of patients achieving American College of Rheumatology (ACR) criteria for 20% (ACR20), 50% (ACR50), and 70% (ACR70) responses along with the disability index of health assessment questionnaire (HAQ), and safety. Patients who were randomized to CinnoRA® or Humira® arms had comparable demographic information, laboratory results, and disease characteristics at baseline. The proportion of patients achieving good and moderate EULAR responses in the CinnoRA® group was non-inferior to the Humira® group at 12 and 24 weeks based on both intention-to-treat (ITT) and per-protocol (PP) populations (all p values >0.05). No significant difference was noted in the proportion of patients attaining ACR20, ACR50, and ACR70 responses in the CinnoRA® and Humira® groups (all p values >0.05). Further, the difference in HAQ scores and safety outcome measures between treatment arms was not statistically significant. CinnoRA® was shown to be non-inferior to Humira® in terms of efficacy at week 24 with a comparable safety profile to the reference product. IRCT.ir, IRCT2015030321315N1 . Registered on 5 April 2015.

1 November 2019 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
SMSeyed Shahabeddin Mortazavi‐Jahromi
Seyed Shahabeddin Mortazavi‐Jahromi
MAMona Aslani
Mona Aslani
SOSaiedeh Omidian
Saiedeh Omidian
AAArman Ahmadzadeh
Arman Ahmadzadeh
ZRZahra Rezaieyazdi
Zahra Rezaieyazdi
AMAbbas Mirshafiey
Abbas Mirshafiey

2 January 2019 in Inflammopharmacology
Verified
Journal Article
Closed access
ZRZahra Rezaieyazdi
Zahra Rezaieyazdi
AFAbid Farooqi
Abid Farooqi
HSHossein Soleymani-Salehabadi
Hossein Soleymani-Salehabadi
AAArman Ahmadzadeh
Arman Ahmadzadeh
MAMona Aslani
Mona Aslani
AMAbbas Mirshafiey
Abbas Mirshafiey

29 March 2020 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
SMSeyed Shahabeddin Mortazavi-Jahromi
Seyed Shahabeddin Mortazavi-Jahromi
AAArman Ahmadzadeh
Arman Ahmadzadeh
ZRZahra Rezaieyazdi
Zahra Rezaieyazdi
MAMona Aslani
Mona Aslani
SOSaiedeh Omidian
Saiedeh Omidian
AMAbbas Mirshafiey
Abbas Mirshafiey
Context: miR-146a, its targets (IRAK1, TRAF6) and NF-κB transcription factor play a fundamental role in rheumatoid arthritis (RA). Positive effects of drug β-d-mannuronic acid (M2000) were proven on their expression in the HEK-Blue hTLR2 cell line, and results of its phase III clinical trial on RA patients were encouraging. Objective: This research aimed to investigate the effects of M2000 on expression of these genes and serum levels of IL-6 and TNF-α as pro-inflammatory cytokines in RA patients. Material and methods: In this study (Trial Registration Number: IRCT2017100213739N10), 12 RA patients (according to the American College of Rheumatology criteria) and 12 healthy subjects (as control group) were selected. The gene expression of miR-146a, IRAK1, TRAF6, and NF-κB were measured at the baseline and after 12 weeks M2000 therapy, using quantitative real-time PCR method. Moreover, the serum levels of IL-6 and TNF-α were evaluated at the similar times by ELISA method. Results: Our findings showed that the gene expression of miR-146a, IRAK1, TRAF6, and NF-κB significantly decreased after 12 weeks M2000 therapy in RA patients (0.81-, 0.68-, 0.79-, 0.82-fold, with p < .05, p < .01, p < .01, p < .05, respectively). Furthermore, the serum levels of IL-6 and TNF-α significantly reduced in these patients after 12 weeks M2000 therapy (both with p < .05). Conclusions: The present research results determined the part of molecular mechanisms of drug M2000 in RA treatment, based on the expression and function modification of miR-146a, IRAK1, TRAF6, NF-κB, IL-6 and TNF-α.

1 June 2016
Verified
Journal Article
Open access
SBShahnaz Bahadori
Shahnaz Bahadori
JSJamshid Salamzadeh
Jamshid Salamzadeh
MKMohammad Kamalinejad
Mohammad Kamalinejad
MAMohammad Reza Shams Ardekani
Mohammad Reza Shams Ardekani
MKMansoor Keshavarz
Mansoor Keshavarz
AAArman Ahmadzadeh
Arman Ahmadzadeh
This study was designed to explore the complementary effects of a combination formulation of olive oil, olive and fig fruits on RA remission indicators. A randomized controlled clinical trial was designed. Adult RA patients were randomly divided into two groups receiving routine Disease-modifying antirheumatic drugs (DMARDs) regimen (control group) and routine DMARDs regimen plus the herbal supplementary formulation of olive oil, fig and olive fruits (intervention group). Patients were followed every 4 weeks for total study period of 16 weeks. In addition to demographic and medical history of the patients, the Disease Activity Score with 28-joint counts based on Erythrocyte Sedimentation Rate (DAS28_ESR) were recorded. SPSS (version 22.0) software was used to analyze data, assuming p<0.05 as significance level. 56 patients (control = 27 and intervention = 29), with mean +/- sd age of 50.91 +/- 12.26 years completed the study. Repeated measures analysis revealed that differences between remission indicators in the two study groups were not statistically significant, however, there was a p = 0.03 for the within-subjects contrast test of the Patient Global Assessment (PtGA), approving a nonlinear change for PtGA with respect to time. No between groups differences in adjunct drug therapy pattern for disease flares were seen. In conclusion, although, non-significant changes in the study variable of DAS28_ESR is in agreement with few previous reports, nevertheless, trends in its reduction in the intervention group along with the significant delayed PtGA score improvements occurred in the intervention group convince us to suggest further investigations on the supplementary olive and fig products, with a longer follow up periods.